Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

72.71 +1.08 (+1.51%)
Delayed Quote Updated: 2:02 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript ↗
Lifyorli's launch and a new metabolic pipeline shaped the quarter. 
Via The Motley Fool
Topics Earnings
News headline image
CORT Q3 2026 deep dive: rapid Lifyorli uptake and pipeline expansion shape outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 64% year on year to $... 
Via StockStory
News headline image
Corcept Therapeutics Q3 Earnings Call Highlights ↗
Corcept Therapeutics (NASDAQ:CORT) reported third-quarter 2026 revenue of $340.5 million, up 33% from the prior quarter and 64% from a year earlier, as growth in its endocrinology business and the... 
Via MarketBeat
Topics Earnings
Corcept Therapeutics (NASDAQ:CORT) Q3 EPS Beat Offset by In-Line Revenue and Reiterated Guidance ↗
Via Chartmill
Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup ↗
Via Chartmill
News headline image
Corcept’s (NASDAQ:CORT) Q3 2026: beats on revenue
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 64% year on year to $34... 
Via StockStory
News headline image
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept (CORT) to report earnings tomorrow: here is what to expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday after market hours. Here’s what to look for. Corcept be... 
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Collegium Pharmaceutical (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 earnings highs and lows: Eli Lilly (NYSE:LLY) vs the rest of the branded pharmaceuticals stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 cash-producing stocks to research further and 1 we find risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Energy
News headline image
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 Cash-Heavy Stock to Keep an Eye On and 2 We Question
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
The past six months have been a windfall for Corcept’s shareholders. The company’s stock price has jumped 201%, hitting $122.93 per share. This was partly du... 
Via StockStory
News headline image
Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Corcept Announces Planned Leadership Transition
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Phibro Animal Health (NASDAQ:PAHC) Vs Peers
Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnin... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 of Wall Street’s Favorite Stocks We Keep Off Our Radar
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
2 Healthcare Stocks to Research Further and 1 We Find Risky
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
News headline image
1 Growth Stock Set to Flourishand 2 We Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Topics Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Surging Stock to Own for Decades and 2 We Brush Off
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Steer Clear Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.